THERAPY DOSSIER · th-2fe6773e1a69

Basic fibroblast growth factor loaded with heparin into a column-shaped agarose gel scaffold, 3 mm diameter by 3 mm length, 4.5 per cent w/v agarose

Biologic · Recombinant basic fibroblast growth factor (FGF-2) delivered from a heparin-loaded agarose gel scaffold; FGF-2 signals through FGFR1-4 receptor tyrosine kinases, heparin acting as an obligate co-receptor that stabilises the ligand and prolongs local release. ChEMBL holds no entity for the protein-plus-scaffold construct.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Recombinant basic fibroblast growth factor (FGF-2) delivered from a heparin-loaded agarose gel scaffold; FGF-2 signals through FGFR1-4 receptor tyrosine kinases, heparin acting as an obligate co-receptor that stabilises the ligand and prolongs local release. ChEMBL holds no entity for the protein-plus-scaffold construct.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01217476 ↗PHASE3completed

Phase III study of 12 weeks treatment with trafermin 0.01% spray in patients with diabetic foot ulcer of neuropathic origin

Diabetic Foot Ulcer of Neuropathic Origin

Enrolment: 207 · Results not recorded

NCT01728844 ↗NAcompleted

Dose verification trial of GUIDOR growth factor enhanced bone graft substitute (rhFGF-2 / beta-TCP) for periodontal defects

Alveolar Bone Loss · Periodontal Diseases

Enrolment: 88 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32440502 ↗2019Reported benefit

Basic fibroblast growth factor and agarose gel promote the ability of immune privilege of allogeneic cartilage transplantation in rats.

RatOtherSprague DawleyMalen = 196 adult male Sprague Dawley rats in total, n = 7 per grou…Local implantation of the agarose gel into the femoral osteochondral defectBasic fibroblast growth factor solution 5 mL at 500 mg/mL a…Gel implanted at the time of defect creation, with allogeneic articular cartila…

Model: Full-thickness osteochondral defect 3.0 mm by 3.0 mm created in the trochlear groove of the distal femur under 10 per cent chloral hydrate anaesthesia at 4 mL/kg, followed by allogeneic or autologous osteochondral cartilage transplantation

At 6 weeks the allogeneic cartilage with agarose gel plus basic fibroblast growth factor group showed smooth integrated graft surfaces of adequate thickness comparable with the autologous group, with International Cartilage Repair Society scores significantly higher than allogeneic cartilage alone…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…

Basic fibroblast growth factor loaded with heparin into a column-shaped agarose gel scaffold, 3 mm diameter by 3 mm length, 4.5 per cent w/v agarose